» Articles » PMID: 20231196

Serum Calprotectin As a Marker for Disease Activity and Severity in Adult-onset Still's Disease

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2010 Mar 17
PMID 20231196
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Calprotectin is a calcium-binding cytosolic protein of the neutrophil, monocyte, and macrophage, and its secretion increases during activation of these cells. Our objective was to measure serum calprotectin concentrations in patients with adult-onset Still's disease (AOSD) and to correlate serum calprotectin with the activity and severity of AOSD.

Methods: We enrolled 25 patients with AOSD and 30 age- and sex-matched healthy controls. Thirty-one serum samples were obtained from patients with AOSD during active or inactive disease and were assayed for calprotectin by ELISA. Clinical and laboratory data related to disease activity and severity were collected at the same time, and systemic scores for disease severity were calculated.

Results: Mean calprotectin levels in patients with AOSD were significantly higher than in controls (57.11 +/- 25.38 ng/ml vs 34.90 +/- 4.85 ng/ml, respectively; p < 0.05). Patients with active AOSD had a significantly higher mean calprotectin level than those with inactive disease (61.26 +/- 25.59 ng/ml vs 35.32 +/- 5.90 ng/ml; p < 0.05). Calprotectin levels decreased significantly after treatment in all 6 patients with AOSD from whom followup samples were obtained (p = 0.028). Serum calprotectin showed strong correlations with serum ferritin (r = 0.686, p < 0.001), lactate dehydrogenase (r = 0.647, p < 0.001), leukocyte count (r = 0.774, p < 0.001), aspartate aminotransferase (r = 0.387, p = 0.042), and C-reactive protein (r = 0.588, p = 0.001), but not with erythrocyte sedimentation rate, arginine aminotransferase, hemoglobin, or platelet count. Serum calprotectin showed a significant correlation with AOSD systemic scores, reflecting disease severity (r = 0.803, p < 0.001).

Conclusion: Serum calprotectin increased in patients with AOSD, in close correlation with disease activity and severity. These findings suggest that serum calprotectin can provide a reliable clinical marker for monitoring the disease activity and severity of AOSD.

Citing Articles

Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.

Bindoli S, Baggio C, Doria A, Sfriso P Drugs. 2024; 84(3):257-274.

PMID: 38441807 PMC: 10982104. DOI: 10.1007/s40265-024-01993-x.


Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline.

Vordenbaumen S, Feist E, Rech J, Fleck M, Blank N, Haas J Z Rheumatol. 2022; 82(Suppl 2):81-92.

PMID: 36520170 DOI: 10.1007/s00393-022-01294-2.


Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment.

Macovei L, Burlui A, Bratoiu I, Rezus C, Cardoneanu A, Richter P Int J Mol Sci. 2022; 23(21).

PMID: 36361602 PMC: 9655522. DOI: 10.3390/ijms232112810.


Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab.

Ghannam K, Zernicke J, Kedor C, Listing J, Burmester G, Foell D J Clin Med. 2021; 10(19).

PMID: 34640417 PMC: 8509487. DOI: 10.3390/jcm10194400.


Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.

Jung J, Kim J, Suh C, Kim H Front Immunol. 2020; 11:583513.

PMID: 33224145 PMC: 7674197. DOI: 10.3389/fimmu.2020.583513.